Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Other Non-Current Liabilities (2024 - 2026)

Maze Therapeutics' Other Non-Current Liabilities history spans 3 years, with the latest figure at $388000.0 for Q1 2026.

  • On a quarterly basis, Other Non-Current Liabilities fell 61.43% to $388000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $388000.0, a 61.43% decrease, with the full-year FY2025 number at $1.1 million, up 12.9% from a year prior.
  • Other Non-Current Liabilities hit $388000.0 in Q1 2026 for Maze Therapeutics, down from $1.1 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for MAZE hit a ceiling of $1.1 million in Q4 2025 and a floor of $388000.0 in Q1 2026.
  • Historically, Other Non-Current Liabilities has averaged $939666.7 across 3 years, with a median of $1.0 million in 2025.
  • Biggest five-year swings in Other Non-Current Liabilities: rose 12.9% in 2025 and later crashed 61.43% in 2026.
  • Tracing MAZE's Other Non-Current Liabilities over 3 years: stood at $969000.0 in 2024, then rose by 12.9% to $1.1 million in 2025, then tumbled by 64.53% to $388000.0 in 2026.
  • Business Quant data shows Other Non-Current Liabilities for MAZE at $388000.0 in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.